Multidisciplinary clinic contributes to the decreasing trend in the number of emergency hospitalizations for amyotrophic lateral sclerosis in Japan

Sugisawa, Tatsuki; Morioka, Harumi; Hirayama, Takehisa; Kano, Osamu; Ebihara, Satoru

doi:10.1016/j.jocn.2022.10.011

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] The distribution of diagnoses associated with emergency hospitalizations identified in our report is similar to that resulting in emergency hospitalizations of patients with ALS in a recent Japanese study. 14 There are several limitations to our analysis, which are inherent in the structure of our randomized study. First, Study 19 was not powered a priori to analyze the novel composite endpoint of death, tracheostomy, PAV, or hospitalization.…”

Section: Recent Observational Studies On Emergency Hospitalizations Inmentioning

confidence: 99%

“…Japanese patients with ALS provide further granularity with respect to the kinds of diagnoses associated with emergency hospitalizations 14 compared with planned hospitalizations. [15][16][17] The distribution of diagnoses associated with emergency hospitalizations identified in our report is similar to that resulting in emergency hospitalizations of patients with ALS in a recent Japanese study.…”

Section: Recent Observational Studies On Emergency Hospitalizations Inmentioning

confidence: 99%

See 1 more Smart Citation

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Brooks

Pioro

Sakata³

et al. 2023

Muscle and Nerve

View full text Add to dashboard Cite

Introduction/AimsIntravenous (IV) edaravone is a US Food and Drug Administration–approved treatment for amyotrophic lateral sclerosis (ALS), shown in clinical trials to slow physical functional decline. In this study we compared the effect of IV edaravone (edaravone‐first group) versus placebo followed by IV edaravone (placebo‐first group) on survival and additional milestone events.MethodsThis work is a post hoc analysis of Study 19/MCI186‐19, which was a randomized, placebo‐controlled, phase 3 study investigating IV edaravone versus placebo. Study 19 and its 24‐week extension have been described previously (NCT01492686). Edaravone‐first versus placebo‐first group time to events for specific milestone(s) were analyzed post hoc. Time‐to‐event composite endpoints were time to death; time to death, tracheostomy, or permanent assisted ventilation (PAV); and time to death, tracheostomy, PAV, or hospitalization.ResultsThe risk for death, tracheostomy, PAV, or hospitalization was 53% lower among patients in the edaravone‐first vs placebo‐first groups (hazard ratio = 0.47 [95% confidence interval 0.25 to 0.88], P = .02). The overall effect of IV edaravone on ALS progression could be seen in the significant separation of time‐to‐event curves for time to death, tracheostomy, PAV, or hospitalization. ALS survival composite endpoint analyses (ALS/SURV) suggested a treatment benefit (least‐squares mean difference) for the edaravone‐first versus the placebo‐first group at week 24 (0.15 ± 0.05 [95% confidence interval 0.06 to 0.25], P < .01) and week 48 (0.11 ± 0.05 [95% confidence interval 0.02 to 0.21], P = .02).DiscussionThese analyses illustrate the value of timely and continued IV edaravone treatment, as earlier initiation was associated with a lower risk of death, tracheostomy, PAV, or hospitalization in patients with ALS.

show abstract

Section: Recent Observational Studies On Emergency Hospitalizations Inmentioning

confidence: 99%

Section: Recent Observational Studies On Emergency Hospitalizations Inmentioning

confidence: 99%

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Brooks

Pioro

Sakata³

et al. 2023

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…The value of multidisciplinary care for patients with ALS is well defined. Patients who are followed in these clinics have longer survival, 24-27 fewer hospitalizations, 9,28 better quality of life, 10 and greater access to therapies for ALS 9,10,29 . A 2021 meta-analysis of six studies demonstrated a mean survival advantage of 141.67 days for patients followed in a multidisciplinary clinic compared with non–multidisciplinary care 26 .…”

Section: Multidisciplinary Care Modelsmentioning

confidence: 99%

Multidisciplinary Clinics in Neuromuscular Medicine

Gwathmey,

Heiman-Patterson

2023

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

Multidisciplinary care is comprehensive, coordinated clinical care across medical disciplines and allied health professions. Neuromuscular disorders, such as amyotrophic lateral sclerosis and muscular dystrophies, are often associated with disabling weakness and extramuscular symptoms and may benefit from care in a model that consolidates numerous clinic visits into a single more efficient multidisciplinary clinic visit. The goal of the neuromuscular multidisciplinary care model is to improve patient outcomes, patient satisfaction, quality of life, access to medications and equipment, and survival. Although the costs of running a multidisciplinary clinic are high, they are likely associated with cost savings from the patient's perspective. Several barriers to acceptance of multidisciplinary clinics include the distance needed to travel to the clinic and the duration of the clinic visit. Telehealth multidisciplinary clinic visits may address some of these concerns. Further study is needed to understand the value of multidisciplinary clinics and is a necessary step toward creating a sustainable model.

show abstract

Caring for people living with ALS in Korea: challenges and possible paths forward

Yeo,

Simmons

2024

Muscle and Nerve

View full text Add to dashboard Cite

Multidisciplinary clinic contributes to the decreasing trend in the number of emergency hospitalizations for amyotrophic lateral sclerosis in Japan

Cited by 6 publications

References 19 publications

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Multidisciplinary Clinics in Neuromuscular Medicine

Caring for people living with ALS in Korea: challenges and possible paths forward

Contact Info

Product

Resources

About